Haematology+Oncology_News

IS PBS LISTED ®

Take Action – Right From the Start 1,2 In the identification and treatment of ALK-positive advanced NSCLC patients XALKORI - The first ALK-directed treatment 3

XALKORI is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). 1

PBS Information: Authority required. Refer to PBS Schedule for full authority information.

Before prescribing please review approved Product Information available at www.pfizer.com.au Minimum Product Information. XALKORI ® (crizotinib 200 mg and 250 mg) Capsules Indications: Treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Contraindications: Hypersensitivity to crizotinib or any excipients. Precautions: Hepatotoxicity, interstitial lung disease (pneumonitis), QT interval prolongation, bradycardia, leucopenia, renal cysts, hepatic impairment, renal impairment, pregnancy, lactation. See full PI for details. Interactions: CYP3A & CYP2B6 inhibitors, CYP3A inducers, substrates of P-glycoprotein. See full PI for details. Adverse Effects: Very common: vision disorder, nausea, diarrhoea, vomiting, constipation, elevated transaminases, oedema, fatigue, decreased appetite, dysgeusia, neuropathy, dizziness, neutropenia. See full PI for details. Dosage and Administration: Detection of ALK-positive NSCLC is necessary for selection of patients. The recommended dose of crizotinib is 250 mg twice daily. See full PI for details. Before prescribing, refer to the full Product Information available from Pfizer Australia Pty Ltd. ® Registered trademark V10913 References: 1. XALKORI ® (crizotinib) Approved Product Information. 2. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (V4. 2015). Accessed February 12, 2015 from http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Referenced with permission. 3. Ou S-H. Expert Rev Anticancer Ther. 2012;12:151-162. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Non-Small Cell Lung Cancer.V.4.2015. © 2015 National Comprehensive Cancer Network, Inc.All rights reserved.Accessed February 12, 2015.To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK ® , NCCN ® , NCCN GUIDELINES ® , and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. ® Registered Trademark. Pfizer Australia Pty Limited. Pfizer Medical Information: 1800 675 229. 38–42 Wharf Road, West Ryde, NSW 2114. PP-XLK-AUS-0057 JULY 2015. S&H PFIXA1062A-H-F